Brought to you by 
DeveloGen licenses DiaPep277 to start-up Andromeda Biotech; later concludes
13 Nov 2014
Executive Summary
The Israeli subsidiary of DeveloGen AG (metabolic and endocrine disorders) has licensed its DiaPep277 candidate to newly formed diabetic therapeutics developer Andromeda Biotech. DiaPep277 is a peptide derived from human heat-shock protein HSP60, an immunomodulator known for preventing the destruction of insulin-secreting pancreatic cells in Type I diabetes.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DeveloGen licenses DiaPep277 to start-up Andromeda Biotech; later concludes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice